Remdesivir “Shortening Patient Recovery” Clinical Trial Final Report October 9, 7:31
Research groups such as the National Institutes of Health have published the final report of an international clinical trial of the antiviral drug remdesivir, which can be expected to shorten the recovery time for patients with the new coronavirus and prevent its aggravation. I showed the view.
On the 8th, research groups such as the National Institutes of Health (NIH) in the United States published the final report of an international clinical trial of the antiviral drug remdesivir in the medical journal "New England Journal of Medicine".
According to the study, the study was conducted in about 1000 adults who were hospitalized with the new coronavirus infection in 10 countries including the United States and Japan, and the group who received remdesivir for up to 10 days and the group who did not receive it. I compared the progress with.
As a result, the median time required for patients to recover to a certain extent was 10 days in the treated group, which was shorter than the 15 days in the non-treated group, and the degree of recovery on the 15th day from the start of treatment was also higher. It was good.
For this reason, the research group has expressed the view that it can be expected to shorten the time required for recovery of patients with the new coronavirus and prevent its aggravation.
Remdesivir was approved in Japan as a special case in May, but in the United States it is only an urgent license and has not been officially approved.
However, it is also known that it was recently administered to President Trump who was infected with the new coronavirus, and it is expected that the movement toward approval will accelerate in the United States as a result of this result.